Yu Sehyeon

Dr. Yu Sehyeon

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2023 in Journal of Liver Cancer
Verified
Journal Article
Open access
PDF file
YSYu Sehyeon
Yu Sehyeon
HJHye-Sung Jo
Hye-Sung Jo
YYYoung-Dong Yu
Young-Dong Yu
YCYoo Jin Choi
Yoo Jin Choi
DKDong-Sik Kim
Dong-Sik Kim
Background/Aims: Although the Barcelona Clinic Liver Cancer staging system seems to underestimate the impact of curative-intent surgical resection for multifocal hepatocellular carcinoma (HCC), recent studies have indicated favorable results for the surgical resection of multiple HCC. This study aimed to assess clinical outcomes and feasibility of surgical resection for multifocal HCC with up to three nodules compared with single tumor cases.Methods: Patients who underwent surgical resection for HCC with up to three nodules between 2009 and 2020 were included, and those with the American Joint Committee on Cancer (AJCC) 8th edition, T1 and T4 stages were excluded to reduce differences in disease distribution and severity. Finally, 81 and 52 patients were included in the single and multiple treatment groups, respectively. Short- and long-term outcomes including recurrence-free survival (RFS) and overall survival (OS), were evaluated.Results: All patients were classified as Child-Pugh class A. RFS and OS were not significantly different between the two groups (P=0.176 and P=0.966, respectively). Multivariate analysis revealed that transfusion and intrahepatic metastasis were significantly associated with recurrence (P=0.046 and P=0.005, respectively). Additionally, intrahepatic metastasis was significantly associated with OS (hazard ratio, 1.989; 95% confidence interval, 1.040-3.802; P=0.038).Conclusions: Since there was no significant difference in survival between the single and multiple groups among patients with AJCC 8th stage T2 and T3, surgical resection with curative intent could be considered with acceptable long-term survival for selected patients with multiple HCC of up to three nodules.

20 July 2022 in Korean Journal of Transplantation
Verified
Journal Article
Open access
PDF file
YSYu Sehyeon
Yu Sehyeon
YCYoo Jin Choi
Yoo Jin Choi
HJHye-Sung Jo
Hye-Sung Jo
PPPyoung-Jae Park
Pyoung-Jae Park
DKDong-Sik Kim
Dong-Sik Kim
YYYoung-Dong Yu
Young-Dong Yu
Sehyeon Yu, Yoo Jin Choi, Hye-Sung Jo, Pyoung-Jae Park, Dong-Sik Kim, Young-Dong Yu. Korean J Transplant -0001;0:. https://doi.org/10.4285/kjt.22.0020

31 July 2024 in JOURNAL OF ACUTE CARE SURGERY
Verified
Journal Article
Open access
PDF file
YSYu Sehyeon
Yu Sehyeon
HLHanyoung Lee
Hanyoung Lee
JLJae-myeong Lee
Jae-myeong Lee
The A-1000 (Elmeca, Co. Ltd., Seoul, Korea) electrical automatic airway suction device, was designed to operate as a customizable repeated closed suction device. It can be used for patients with intubation or tracheostomy tubes. This is the first recorded case of the use of the A-1000 in a general ward patient with a tracheostomy tube. A 91-year-old man presented having attempted suicide by hanging and was admitted to this institution. Although extubation was performed in the intensive care unit, the patient required 2 reintubations. The tracheostomy was performed, and the A-1000 was applied. After weaning from mechanical ventilation, the patient was transferred to the General Ward with a tracheostomy tube in place for effective removal of sputum by the A-1000. The tracheostomy tube was successfully removed, and the patient was discharged. The effectiveness and safety of the A-1000 needs further study by expanding the applications of this device.

14 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YSYu Sehyeon
Yu Sehyeon
HJHye-Sung Jo
Hye-Sung Jo
YYYoung-Dong Yu
Young-Dong Yu
PPPyoung-Jae Park
Pyoung-Jae Park
HHHyung-Joon Han
Hyung-Joon Han
DKDong-Sik Kim
Dong-Sik Kim
Background: Although advancements in desensitization protocols have led to increased ABO-incompatible (ABOi) living-donor liver transplantation (LDLT), a higher biliary complication rate remains a problem. This study evaluated the effect of baseline anti-ABO antibody titers before desensitization on biliary complications after ABOi LDLT. Methods: The study cohort comprised 116 patients in the ABO-compatible group (ABOc), 29 in the ABOi with the low titer (<1:128) group (ABOi-L), and 14 in the high titer (≥1:128) group (ABOi-H). Results: Biliary complications occurred more frequently in the ABOi-H group than in the ABOi-L and ABOc groups (7 [50.0%] vs. 8 [27.6%] and 24 [20.7%], respectively, p = 0.041). Biliary complication-free survival was significantly worse in the ABOi-H group than in the other groups (p = 0.043). Diffuse intrahepatic biliary strictures occurred more frequently in the ABOi-H group than in the other groups (p = 0.005). Multivariable analysis revealed that the high anti-ABO antibody titer (≥1:128) is an independent risk factor for biliary complications (hazard ratio 3.943 [1.635–9.506]; p = 0.002). Conclusions: A high baseline anti-ABO antibody titer (≥1:128), female sex, and hepatic artery complications are significant risk factors for biliary complications.

8 June 2023 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Closed access
PDF file
YSYu Sehyeon
Yu Sehyeon
HJHye-Sung Jo
Hye-Sung Jo
YYYoung-Dong Yu
Young-Dong Yu
SKSang Jin Kim
Sang Jin Kim
DKDong-Sik Kim
Dong-Sik Kim
Se Hyeon YU, Hye-Sung JO, Young-Dong YU, Sang Jin KIM, Dong-Sik KIM*. Ann Hepatobiliary Pancreat Surg 2023;27:S197. https://doi.org/10.14701/ahbps.2023S1.LV-PP-5-4

27 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YSYu Sehyeon
Yu Sehyeon
HJHye-Sung Jo
Hye-Sung Jo
YYYoung-Dong Yu
Young-Dong Yu
YCYoo-Jin Choi
Yoo-Jin Choi
SJSu-Min Jeon
Su-Min Jeon
DKDong-Sik Kim
Dong-Sik Kim
Background: Hepatocellular carcinoma (HCC) with hepatic vein invasion (HVI) is classified as advanced stage and palliative management is the primary treatment option. This study compared the long-term outcomes of curative and non-curative treatments in patients of HCC with HVI. Methods: Data were obtained from a retrospective multicenter cohort of the Korean Primary Liver Cancer Registry. We reviewed 18,315 patients newly diagnosed with HCC between 2008 and 2019. After propensity score matching based on the albumin-bilirubin (ALBI) score; tumor number, and tumor size, clinical outcomes were compared between the curative group (n = 42, 29.0%) undergoing surgical resection or local ablation and the non-curative group (n = 103, 71.0%) receiving other treatments. Results: Tumor burdens such as tumor number, maximum tumor size, levels of alpha-fetoprotein (AFP), and protein induced by absence of vitamin K or antagonist-II did not differ significantly between the groups (p = 0.672, p = 0.143, p = 0.153 and p = 0.651, respectively). In long-term outcomes, the overall survival (OS) and cancer-specific survival (CSS) were significantly better in the curative group compared to the non-curative group (p < 0.001, both). Multivariate analysis indicated that non-curative treatment, ALBI grade ≥ 2, and AFP ≥ 400 ng/mL were common risk factors for OS and CSS. Conclusions: Curative-intent treatment has the potential to significantly enhance long-term outcomes in selected patients of HCC with HVI who preserved liver function and performance status.